Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  Roche Holding Ltd.    RHO5   CH0012032048

ROCHE HOLDING LTD. (RHO5)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Latest news on ROCHE HOLDING LTD.
04/23ROCHE : New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions..
BU
04/18GSK flags pharma M&A ambitions by poaching Roche deal-maker
RE
04/18Shire faces criticism on CEO pay policy as crunch week looms
RE
04/17ROCHE : FDA Grants Breakthrough Therapy Designation for Genentech’s HEMLIB..
BU
04/16GENENTECH : to Present New Data at AAN Highlighting Extensive Research for OCREV..
BU
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/03Roche's Alecensa Approved in Switzerland
DJ
03/28ROCHE : Tokyo court rejects Shire claim against Roche haemophilia drug
RE
03/26Singapore pharma on recovery path after worst output in decades
RE
03/26Roche's Tecentriq Improves Lung Cancer Treatment Results With Avastin
DJ
03/26ROCHE : Phase III IMpower150 Study Showed Genentech’s TECENTRIQ (Atezolizu..
BU
03/22Roche's Lucentis 0.3 Mg Prefilled Syringe Receives FDA Approval
DJ
03/21Britain's use of copycat biotech drugs takes off while U.S. lags
RE
03/21ROCHE : FDA Approves Genentech’s Lucentis (ranibizumab injection) 0.3 mg P..
BU
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
RE
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
RE
03/20Roche says Tecentriq, chemo cut risk of death in type of lung cancer
RE
03/20ROCHE : Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizu..
BU
03/19GLOBAL ARTIFICIAL INTELLIGENCE AND A : Global Artificial Intelligence And Advanc..
AQ
03/19PTC THERAPEUTICS : FIREFISH Transitions into Pivotal Phase
AQ
03/19FOUNDATION MEDICINE : CMS issues final coverage decision for NGS cancer tests
AQ
03/17ROCHE : Federal Contracts Awarded to Companies in Indiana (March 17)
AQ
03/17ROCHE : Federal Contracts Awarded by Federal Agencies in North Dakota (March 17)
AQ
03/16KNOW ABOUT CERVICAL CANCER MARKET IN : New Research: Cervical Cancer Market &nda..
AQ
03/16ROCHE : Q-- 6 month Bridge ROCHE - IOWA CITY
AQ
03/16ROCHE : Q-- 6 month Bridge ROCHE - DES MOINES
AQ
03/16ROCHE : $1.31 Million Federal Contract Awarded to Roche Diagnostics
AQ
03/16ROCHE : Vintage Drawer Pulls and Handles Bring High Aesthetics to Every Home
AQ
03/16ROCHE : $432,000 Federal Contract Awarded to Roche Diagnostics
AQ
03/16ROCHE : $375,000 Federal Contract Awarded to Roche Diagnostics
AQ
03/15FOUNDATION MEDICINE : Tango Therapeutics Expands Board of Directors with the Add..
AQ
03/15FOUNDATION MEDICINE : to Present at Cowen and Company's 38th Annual Healthcare C..
AQ
03/15ROCHE HOLDING LTD. : Ex-dividend day for for final dividend
FA
03/14CURIS : Reports Fourth Quarter and Year-End 2017 Financial Results
AQ
03/14ROCHE : BioMed X and Roche announce research collaboration
AQ
03/10CELGENE : Kapeller leaves Nimbus, ending CSO stint defined by virtual drug disco..
AQ
03/10ROCHE : names new head of pharma research and early development
AQ
03/09ROCHE : Changes to the Roche Enlarged Corporate Executive Committee
AQ
03/08CHUGAI PHARMACEUTICAL : HEMLIBRA® Approved by European Commission in Hemophilia ..
AQ
03/08ROCHE : names Pao as Swiss R&D head after Reed exits
RE
03/08ROCHE : Names New Head of Pharma Research and Early Development
DJ
03/07FOUNDATION MEDICINE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
03/07FOUNDATION MEDICINE : reports 4Q loss
AQ
03/07FOUNDATION MEDICINE, INC. : Results of Operations and Financial Condition, Finan..
AQ
03/07ROCHE : GE to Develop Integrated Decision Support Platform
AQ
03/07Siemens' Healthineers share listing fully subscribed - bookrunner
RE
03/07CIPLA : To Sell Two Roche Biologics In India
AQ
03/06PEOPLE BEFORE PROFITS : Roche’s innovative employment practices
AQ
03/06Glaxo's Encouraging Asthma & HIV Data at Medical Meetings
AQ
03/05ROCHE : Refuse skips
AQ
03/05FOUNDATION MEDICINE, INC. : Entry into a Material Definitive Agreement (form 8-K..
AQ
03/05ROCHE : Trial drug given `accelerated status` paves way for faster approval
AQ
03/03MetroWest Business Digest for March 4, 2018
AQ
03/03IONIS PHARMACEUTICALS : drug for Huntington's disease shows early signs of effec..
AQ
03/02ROCHE : achieves two major milestones in the evolution of decision support platf..
PR
03/02CIPLA : partners with Roche Pharma India to create greater access to key medicin..
AQ
03/02CHUGAI PHARMACEUTICAL : HEMLIBRA Approved by European Commission in Hemophilia A..
AQ
03/02ROCHE : Europe approves first therapy for haemophilia A with inhibitors in over ..
AQ
03/02BIOMERIEUX : Six Leading Pharma Firms to Participate at Pharmaceutical Microbiol..
AQ
03/01BIOMERIEUX : Six leading pharma firms to participate at Pharmaceutical Microbiol..
AQ
03/01CIPLA : Roche and Cipla tie up to market anti cancer drugs
AQ
03/01ROCHE : Chugais Hemlibra wins green light for bleeding disorder
AQ
03/01PFIZER : Roche and Allergan Weigh FDA Plans for Patient-Focused Drug Development..
AQ
03/01Cipla, roche in first deal to sell cancer drugs
AQ
02/28GLOBAL BIOLOGICS AND BIOSIMILARS MAR : 99strategy added a depth and professional..
AQ
02/28BIOMERIEUX : Six leading pharma firms to participate at Pharmaceutical Microbiol..
AQ
02/28ROCHE : European Commission approves Roche's Hemlibra for people with haemophili..
AQ
02/28TESARO : Announces Collaboration to Evaluate Combination of ZEJULA (Niraparib) a..
AQ
02/28TESARO : and Roche to combine drugs in bladder cancer trials
AQ
02/28CIPLA : To sell 2 roche drugs in india
AQ
02/27SHIONOGI : New Japanese drug halts flu virus replication in 1 day
AQ
02/27TESARO : Announces Collaboration to Evaluate Combination of ZEJULA and Anti-PD-L..
AQ
02/27ROCHE : LAUNCHES MASS-MARKET GLUCOMETER AT Rs1,099
AQ
1  2  3  4  5  6  7  8  9  10Next
Financials ( CHF)
Sales 2018 55 186 M
EBIT 2018 18 519 M
Net income 2018 11 868 M
Debt 2018 4 199 M
Yield 2018 3,97%
P/E ratio 2018 15,25
P/E ratio 2019 14,53
EV / Sales 2018 3,48x
EV / Sales 2019 3,29x
Capitalization 188 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | RHO5 | CH0012032048 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 259  CHF
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-14.69%192 109
JOHNSON & JOHNSON-9.35%339 783
PFIZER1.13%217 897
NOVARTIS-7.72%204 972
ROCHE HOLDING LTD.-11.72%192 109
MERCK AND COMPANY7.07%158 571